Compare AUBN & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AUBN | PMVP |
|---|---|---|
| Founded | 1907 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 88.8M | 76.8M |
| IPO Year | 1996 | 2020 |
| Metric | AUBN | PMVP |
|---|---|---|
| Price | $25.45 | $1.16 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 1.4K | ★ 296.3K |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | ★ 4.61% | N/A |
| EPS Growth | ★ 13.66 | N/A |
| EPS | ★ 0.63 | N/A |
| Revenue | ★ $619,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $42.11 | ★ N/A |
| Revenue Growth | ★ 0.81 | N/A |
| 52 Week Low | $21.60 | $0.96 |
| 52 Week High | $29.00 | $1.88 |
| Indicator | AUBN | PMVP |
|---|---|---|
| Relative Strength Index (RSI) | 71.26 | 48.32 |
| Support Level | $24.00 | $1.13 |
| Resistance Level | $27.76 | $1.26 |
| Average True Range (ATR) | 0.40 | 0.07 |
| MACD | 0.14 | 0.02 |
| Stochastic Oscillator | 98.13 | 55.32 |
Auburn National Bancorp Inc is a bank holding company registered with the Board of Governors of the Federal Reserve System (the Federal Reserve). As a bank holding company, the Company may diversify into a broader range of financial services and other business activities than are currently permitted to the Bank under applicable laws and regulations. The holding company structure also provides greater financial and operating flexibility than is presently permitted to the Bank. The Company's business is conducted through the Bank and its subsidiaries. Although it has no immediate plansto conduct any other business, the Company may engage directly or indirectly in several activities closely related to banking permitted by the Federal Reserve.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.